Skip to main content
. 2021 Jul 23;13(15):3715. doi: 10.3390/cancers13153715

Figure 2.

Figure 2

Patient case after two cycles with 177Lu-PSMA RLT. Patient with mCRPC, previously treated with Docetaxel, Abiraterone, and Enzalutamide. Pre Lu-PSMA therapy PSA levels were 791 ng/mL, after two cycles of Lu-PSMA therapy, PSA levels declined to 114 ng/mL. Concordantly, the PSMA PET derived tumor volume declined from 245 mL to 55 mL.